Understanding the role of cFLIP in B cell lymphoma pathogenesis (A05)

损害B淋巴细胞死亡的突变导致免疫紊乱，包括淋巴结病、脾肿大和B细胞淋巴瘤。cFLIP是一种关键的细胞死亡抑制剂，其表达升高通常与弥漫性大B细胞淋巴瘤（DLBCL）和霍奇金淋巴瘤（HL）相关，并与肿瘤进展和不良临床结局相关。然而，cFLIP在B细胞生物学和淋巴瘤发生中的确切作用尚未阐明。该项目的主要目的是表征cFLIP在DLBCL的发病机制和进展中的作用，并确定如何将其抑制用于淋巴瘤的治疗。

Mutations that impair B lymphocyte death lead to immune disorders, including lymphadenopathy, splenomegaly and B cell lymphoma. cFLIP is a key cell death inhibitor whose elevated expression has been frequently associated with diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL) and correlates with tumor progression and poor clinical outcome. However, the exact role of cFLIP in B-cell biology and lymphomagenesis has not been elucidated, yet. The major objective of this project is to characterize the role of cFLIP in the pathogenesis and progression of DLBCL and determine how its inhibition could be exploited for the treatment of lymphoma.